Calling all dedicated blood and biotherapies professionals! AABB encourages all members to apply to join one of its committees for 2023. Applications are being accepted through Feb. 15, and the new term will begin in the summer of 2023.
AABB updated the Circular of Information for the Use of Human Blood and Blood Components web page following the Food and Drug Administration’s approval of new language to be inserted in the December 2021 Circular.
AABB will host a Hot Topic Discussion on Aug. 18 to discuss the potential impact of long-acting, injectable cabotegravir as pre-exposure prophylaxis (PrEP) for the prevention of HIV. The Food and Drug Administration approved the injectable medication (Apretude, Viiv Healthcare) in December 2021.